REP 2165-Mg

REP 2165-Mg · Replicor Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REP 2165-Mg, covering 2019-09-10 to 2019-09-10. Get the full timeline:

Most recent: Clinical Trial Update: REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection [Phase 2]